Triple Agonism Based Therapies for Obesity

Current Cardiovascular Risk Reports · Published 2025-07-28 · DOI 10.1007/s12170-025-00770-z

Authors being retrieved — see the publisher record. https://doi.org/10.1007/s12170-025-00770-z

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2025

Related articles

Glucagon-like peptide-1 and peptide YY multi-agonism with GEP44 to optimize weight loss and glycemic control while reducing gastrointestinal side effects: the future of anti-obesity pharmacotherapy? · Frontiers in Endocrinology · 2026 · Cites or is cited by this article
An updated overview of alkaloids for the prevention and treatment of metabolic dysfunction-associated steatotic liver disease · Frontiers in Pharmacology · 2026 · Cites or is cited by this article
Integrating Digital Coaching into Cardiac Practice: Strategies to Advance Health Equity · Current Cardiovascular Risk Reports · 2024 · Same journal
Mitral Valve Dysplasia: An Updated Review · Current Cardiovascular Risk Reports · 2024 · Same journal
Remote Monitoring in Cardiovascular Diseases · Current Cardiovascular Risk Reports · 2023 · Same journal
Compounded GLP-1 Receptor Agonists in the Post-Shortage Era: Costs, Safety and Regulatory Challenges · Current Cardiovascular Risk Reports · 2026 · Same journal
Impact of Lipid Lowering Therapies on the Primary Prevention of Atherosclerotic Cardiovascular Disease · Current Cardiovascular Risk Reports · 2025 · Same journal
Addressing Disparities in the Screening and Treatment of Dyslipidemia – A Call to Action · Current Cardiovascular Risk Reports · 2025 · Same journal
Artificial Intelligence Across the Continuum of Atrial Fibrillation Screening, Diagnosis, and Treatment · Current Cardiovascular Risk Reports · 2024 · Same journal
Racial and Ethnic Disparities in Heart Failure with Preserved Ejection Fraction: Epidemiology, Diagnosis, Management and Outcomes · Current Cardiovascular Risk Reports · 2024 · Same journal